Unknown

Dataset Information

Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy.


ABSTRACT:

Background

Pivotal trials of chimeric antigen receptor T-cell (CAR-T) have identified common toxicities but may have been underpowered to detect cardiovascular and pulmonary adverse events (CPAEs).

Objectives

This study sought to investigate CPAEs associated with commercial CD19-directed CAR-T therapy.

Methods

In this retrospective, pharmacovigilance study, the authors used the Food and Drug Administration adverse event reporting system to identify CPAEs associated with axicabtagene-ciloleucel and tisagenlecleucel. The authors evaluated disproportionate reporting by the reporting odds ratio (ROR) and the lower bound of the information component 95% credibility interval (IC025 >0 is deemed significant). Significant associations were further adjusted to age a

SUBMITTER: Goldman A 

PROVIDER: S-EPMC8562317 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature